Viyash Scientific Q4 FY26 results: 780% sales jump

Key takeaway from the March 2026 quarter

Viyash Scientific reported a strong year-on-year improvement in its March 2026 quarter, led by a sharp rise in revenue and profitability. The company’s standalone quarterly numbers showed steep growth on a low base from March 2025. Another set of audited results also highlighted a turnaround from losses to profits at both standalone and consolidated levels. The published data includes multiple result snapshots, some of which differ on profit and revenue for the same quarter. What is consistent across the reports is the scale of improvement in operating performance versus the year-ago period. Investors also tracked the stock’s mixed near-term performance, despite a positive one-year return.

Standalone quarterly performance (as reported)

For the standalone March 2026 quarter, net sales were reported at ₹372.49 crore, up 779.97% from ₹42.33 crore in March 2025. Quarterly net profit was reported at ₹35.81 crore, up 746.57% from ₹4.23 crore in March 2025. EBITDA stood at ₹82.44 crore, up 772.38% from ₹9.45 crore in the year-ago quarter. Earnings per share (EPS) was reported at ₹0.82 in March 2026 versus ₹0.17 in March 2025. A separate table of standalone quarterly results also listed net sales from operations at ₹372.49 crore for March 2026 and ₹341.64 crore for December 2025, compared with ₹42.33 crore for March 2025. These figures indicate a sharp expansion in scale within a year, and sequential growth into the March quarter versus December.

Audited results snapshot also flags turnaround

Viyash Scientific also announced audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, describing a turnaround in profitability. In that audited snapshot, Q4 consolidated net profit was reported at ₹52.11 crore against a loss of ₹26.24 crore a year earlier. Standalone net profit in the same audited release was reported at ₹66.40 crore compared with a loss of ₹32.20 crore in Q4 FY25. Consolidated revenue from operations for the quarter was stated at ₹920.0 crore, compared with ₹772.31 crore a year ago. The audited summary also said EBITDA margins expanded by 590 basis points.

Different Q4 revenue and profit figures across reports

Alongside the audited snapshot, another update in the provided data said net profit rose 459.12% to ₹52.11 crore in the quarter ended March 2026, and sales rose 129.02% to ₹919.96 crore compared with ₹401.70 crore in the year-ago quarter. Separately, the standalone headline numbers reported net sales of ₹372.49 crore and net profit of ₹35.81 crore for March 2026. These variations suggest the dataset includes both standalone and consolidated metrics, and also mixes different reporting formats and comparisons. Because the figures are presented as-is across multiple excerpts, readers should treat them as separate reported snapshots rather than a single reconciled statement.

Quarterly trend data points available in the dataset

A quarterly table in the provided information lists total income at ₹935.88 crore for March 2026, versus ₹872.39 crore in December 2025 and ₹403.36 crore in March 2025. It also lists total expenses at ₹796.12 crore in March 2026 versus ₹782.57 crore in December 2025 and ₹371.92 crore in March 2025. Reported EBIT for March 2026 was ₹139.76 crore, compared with ₹89.82 crore in December 2025 and ₹31.44 crore in March 2025. These lines indicate both higher scale and improved operating outcomes versus the year-ago quarter. The same table shows a sharp step-up in income between September 2025 and December 2025.

FY26 full-year growth (reported)

For the year ended March 2026, sales were reported at ₹3,420.31 crore, up from ₹3,006.84 crore in the year ended March 2025. Another audited summary stated total standalone revenue from operations for FY26 at ₹3,420.31 crore, matching the full-year sales figure. The audited summary also reported standalone net profit for FY26 at ₹224.6 crore versus ₹15.8 crore in FY25. Annual EBITDA was reported at ₹702.5 crore, up 59.6% year-on-year, with an EBITDA margin of 20.5% and a year-on-year improvement of 590 basis points. The same summary reported a gross margin of 54.3% for the year.

Market impact: stock move and investor lens

Viyash Scientific shares closed at ₹228.73 on May 18, 2026 (NSE), as per the provided data. The stock delivered -9.23% returns over the last six months, while it was up 29.01% over the last 12 months. This split performance indicates that while the longer-term price trend remained positive, the recent half-year was weak. With quarterly numbers showing large year-on-year jumps, the market’s focus often shifts to whether earnings gains are sustained across quarters. The dataset also includes a note that December 2025 consolidated net sales were ₹858.41 crore, and December 2025 standalone net sales were ₹341.64 crore.

Operational indicators highlighted in the dataset

The provided information includes commentary that Q3 FY26 revenue of ₹858.41 crore was the company’s highest-ever quarterly sales, up 0.95% sequentially and 10.90% year-on-year. It also stated operating profit (PBDIT excluding other income) rose to ₹175.63 crore in Q3 FY26, with an operating margin of 20.46%. The same excerpt said consolidated net profit in Q3 FY26 was ₹38.44 crore, down from ₹54.91 crore in Q2 FY26 and from ₹44.61 crore in Q3 FY25. Another note cited “strong demand for anthelmintics and pain management APIs” as a factor behind recent performance.

Key numbers table (as reported in the dataset)

Why the March 2026 quarter matters

The standout feature in the March 2026 updates is the magnitude of year-on-year improvement across revenue, EBITDA and profit. On the standalone set of numbers, growth rates above 700% reflect both operational improvement and the low base in March 2025. The audited snapshot’s “turnaround” framing reinforces that profitability shifted from losses to profits in the year-ago comparison. For investors, the combination of higher reported margins and higher revenue scale is an important signal, especially when accompanied by detailed quarterly expense and EBIT lines. At the same time, the mixed stock return profile suggests the market may already be balancing strong reported results against recent quarterly volatility indicated by Q3 profit movement. Any clearer read-through typically comes from consistent segment disclosures and reconciled standalone versus consolidated reporting.

Conclusion

Viyash Scientific’s March 2026 quarter was reported as a sharp improvement on both standalone and consolidated bases, with strong growth in revenue and profitability and an audited turnaround from losses. The next set of quarterly disclosures will be watched for consistency between standalone and consolidated performance, and for whether margins remain near the levels reported for FY26.